Dybly AG

Swiss Biotech Association

Not a member

Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation).

http://www.dybly.com

Location

Bäumleingasse 18, 4051 Basel

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2007
Number of employees in Switzerland

1-9

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Limula SA

Limula SA is developing a platform technology to enable scale out of cell therapy manufacturing, directly at the point of care. We support companies at all stages of the life cycle of their therapies, from R&D to routine production.
La Tour-de-Peilz

Member

Laevoroc Oncology AG

Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies that leverages word-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
Hünenberg

Member

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil

Member